Free Cardiology CME

In this online, self-learning activity:

Pulmonary hypertension (PH) comprises five etiologic groups; Group I, pulmonary arterial hypertension (PAH), is a precapillary entity defined hemodynamically by right‑heart catheterization: mean pulmonary artery pressure >20 mm Hg, pulmonary artery wedge pressure ≤15 mm Hg, and pulmonary vascular resistance ≥3 Wood units. PAH is uncommon but consequential; estimates place U.S. prevalence near 10.6 per million, with contemporary data showing rarity yet meaningful population burden. Sex differences are notable—women predominate, while men may experience more severe trajectories—underscoring the need for sex‑aware assessment. Multinational reviews suggest incidence and prevalence remain non‑trivial, with enduring morbidity and mortality despite therapeutic gains.

In this accredited CME activity, meet a patient who presents with right lower extremity pain with exertion. What will your next steps be in the management of this patient? This activity will discuss modifiable cardiovascular risk factors, sex-specific markers of risk, and management of diabetes in the presence of cardiovascular disease. The activity starts with an introduction to a patient scenario, followed by a case-related question and brief answer explanations.

Guideline updates and recommendations are key patient management tools for cardiac care. This accredited educational activity is designed for primary care physicians and presents a curated series of posts and data centered on the updated AHA/ACC/HFSA guidelines for the management of heart failure. It provides a comprehensive review of the latest evidence-based recommendations, critically examines the clinical trial data behind these guidelines, and underscores the clinical significance of early initiation of guideline-directed medical therapies and timely specialist referral to optimize patient outcomes in heart failure care.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment from the ACC 2025 annual meeting.

This CME activity discusses the diagnosis and treatment of ATTR-CM and highlights key updates on ATTR-CM treatment presented at the HFSA Annual Scientific Meeting 2025 and AHA Scientific Sessions 2025.

In this #CME #MedX, get the latest guidance on managing hypertrophic cardiomyopathy (HCM), including confirming an obstructive HCM (oHCM) diagnosis, integrating recent clinical information on cardiac myosin inhibitor treatments, and addressing patients’ concerns and questions about living with HCM.

In this CME activity, discover the latest information on investigational factor XI/XIa inhibitors, including results from completed clinical trials and news about ongoing clinical trials, to explore their potential role in managing stroke risk in patients with atrial fibrillation (AF).